Chapman Steven Leonard sold $526K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,273 shares of Natera, Inc. (NTRA) at $413.31 ($0.53M total) on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Oct 3, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosure provides new, material information about insider sentiment, which may influence short‑term trading decisions.

02

Market read

An insider sale by the CEO is a noteworthy event for traders monitoring Natera's stock, though the monetary size is modest.

03

What to watch

The 10b5-1 plan pre‑arranged nature may mitigate negative interpretation.

Relevance 4/10Novelty 4/10Timing: post‑market filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the CEO's recent sale.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

CEO Steven Leonard sold 1,273 shares for $526K via a 10b5-1 plan, reducing his holdings to 96,926 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

Insider sales, especially by a CEO, are often viewed as a negative signal, though the amount is modest relative to the company's market cap.

Market effects

Minimal impact on the broader genetic testing sector.

Limited to U.S. markets where Natera trades.

Low; the filing does not affect global market dynamics.

Counterpoint

The sale could be a routine portfolio rebalancing and not indicative of company fundamentals.

Key entities

  • Steven Leonard

    CEO and President of Natera, Inc.

  • Natera, Inc.

    Genomics testing company listed on NASDAQ.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.